Compare · NVO vs ZNTL
NVO vs ZNTL
Side-by-side comparison of Novo Nordisk A/S (NVO) and Zentalis Pharmaceuticals Inc. (ZNTL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and ZNTL operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 612.5x ZNTL ($363.8M).
- Over the past year, NVO is down 21.8% and ZNTL is up 258.5% - ZNTL leads by 280.2 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 2 for ZNTL).
- NVO has more recent analyst coverage (25 ratings vs 18 for ZNTL).
- Company
- Novo Nordisk A/S
- Zentalis Pharmaceuticals Inc.
- Price
- $50.31-2.25%
- $5.09+11.50%
- Market cap
- $222.81B
- $363.8M
- 1M return
- +15.47%
- +44.81%
- 1Y return
- -21.78%
- +258.45%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 5
- 2
- Recent ratings
- 25
- 18
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidates are the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer; and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, as well as in Phase 1b clinical trial in combination with chemotherapy in patients with advanced ovarian cancer. The company also develops ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest ZNTL
- Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026
- Mizuho initiated coverage on Zentalis Pharma with a new price target
- Director Johnson David Michael was granted 57,100 shares, increasing direct ownership by 23% to 307,521 units (SEC Form 4)
- Director Skvarka Jan was granted 57,100 shares, increasing direct ownership by 28% to 264,254 units (SEC Form 4)
- Director Walker Luke Nathaniel was granted 57,100 shares, increasing direct ownership by 40% to 201,384 units (SEC Form 4)
- Director Kariuki Enoch was granted 57,100 shares, increasing direct ownership by 42% to 194,465 units (SEC Form 4)
- Director Myers Scott Dunseth was granted 57,100 shares, increasing direct ownership by 17% to 395,895 units (SEC Form 4)
- Zentalis Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director Campbell Shannon was granted 114,200 shares (SEC Form 4)